echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Iraq, Pakistan and other authorized emergency use of the national pharmaceutical group China Bio-New Crown Vaccine

    Iraq, Pakistan and other authorized emergency use of the national pharmaceutical group China Bio-New Crown Vaccine

    • Last Update: 2021-01-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Iraq's national drug administration has approved a new crown vaccine produced by China's National Pharmaceutical Group for emergency use, Iraqi media reported Thursday.
    Iraqi Ministry of Health spokesman Saif Badr told Xinhua that the Chinese vaccine meets the scientific standards set by Iraq's National Drug Screening Bureau, so Iraq approved the emergency use of the new crown vaccine produced by Chinese organisms in Iraq.
    According to the Iraqi Ministry of Health announced on the 19th, Iraq added 823 new crown confirmed cases on the same day, a total of 609,852 confirmed cases;
    , Jan. 20 (Xinhua) -- Pakistan's Drug Administration has granted China's bio-new crown inactivated vaccine emergency use authorization, the second new crown vaccine approved for emergency use in Pakistan.
    , according to the official website of the Pakistan Drug Administration, the agency at the 18th meeting of the Registration Commission approved the granting of China's biological new crown inactivated vaccine emergency use authorization.
    according to the official website of the Ministry of Health, as of 8 pm local time on the 20th, the country has confirmed a total of 524,783 new crown cases, a total of 11,103 deaths, a cumulative cure of 478,517 cases.
    , Morocco was approved for emergency use Xinhua News Agency, Rabat, January 23, morocco's Ministry of Health issued a communique on the 22nd, Morocco officially approved the emergency use of Chinese biological new crown inactivated vaccine in Morocco.
    decision by the National Authorization Committee, part of the Ministry of Health, after a careful evaluation of China's bio-new crown vaccine, which is valid for 12 months, the Ministry of Health said in a statement.
    Ministry of Health issued a notice on the 22nd, will be officially launched next week, priority vaccination for the new coronavirus susceptible population in line with the requirements.
    Ministry of Health of Morocco reported 950 new confirmed cases on the 23rd, a total of 465,769 confirmed cases, of which 441,693 cases were cured and 8128 deaths were reported.
    In order to implement President Xi Jinping's important speech and instructions on the development and production of the new crown vaccine and the chinese new crown vaccine as a global public product, Chinese bio-organisms has made every effort to speed up the clinical study of the new crown inactivated vaccine III.
    , phase III clinical studies have been conducted in the United Arab Emirates, Bahrain, Egypt, Jordan, Peru, Argentina, Morocco and other countries, making it the largest and fastest-growing clinical study of the new crown vaccine in the world.
    to date, more than 60,000 inoculated volunteers, covering 125 nationalities, have been approved for emergency use in nine countries except ours and have been approved for listing in 2 countries.
    December 31, 2020, the State Council Joint Prevention and Control Mechanism held a press conference, the State Drug Administration announced that on December 30, according to the conditions approved the China Bio-Beijing Institute of Biological Products new coronavirus inactivated vaccine conditional listing.
    Next, China Bio will make every effort to do a good job in the research and development and production of the new crown vaccine, continue to carry out Phase III. clinical trials, in order to achieve the new crown vaccine as a global public product accessibility and affordability to provide a strong support for China's contribution.
    source: Xinhua News Agency
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.